Report Type : Therapy Reports

Report Category : Oncology

Report Subcategory : Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer

Price : 1099.00

Date : December 2022

Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer : Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Top 50 Key Players:
 

1. Johnson & Johnson
2. F. Hoffmann-La Roche Ltd
3. Pfizer Inc
4. Bayer AG
5. Novartis AG
6. Merck & Co Inc
7. Sanofi
8. Abbott Laboratories
9. Bristol-Myers Squibb Co
10. AstraZeneca Plc
11. Amgen Inc
12. Gilead Sciences Inc
13. Boehringer Ingelheim International GmbH
14. Fujifilm Holdings Corp
15. Otsuka Holdings Co Ltd
16. Astellas Pharma Inc
17. Regeneron Pharmaceuticals Inc
18. Eisai Co Ltd
19. A. Menarini Industrie Farmaceutiche Riunite Srl
20. CareGroup Inc
21. Orion Corp
22. Hanmi Science Co Ltd
23. SRI International
24. Corcept Therapeutics Inc
25. Halozyme Therapeutics Inc
26. Nektar Therapeutics
27. Athenex Inc
28. Panacea Biotec Ltd
29. Arvinas Inc
30. Salarius Pharmaceuticals Inc
31. CTI BioPharma Corp
32. AnGes Inc
33. TBG Diagnostics Ltd
34. MEI Pharma Inc
35. Merrion Pharmaceuticals Plc
36. e-Therapeutics Plc
37. Cantex Pharmaceuticals Inc
38. Oncologie Inc
39. Bio-Cancer Treatment International Ltd
40. Celtek Bioscience LLC
41. Peking University
42. Metromedia Bio-Science LLC
43. University of Tokyo
44. Hebei General Hospital
45. NantWorks LLC
46. Mediolanum farmaceutici SpA
47. Fujifilm Holdings Corporation
48. Jyant Technologies Inc
49. DexTech Medical AB
50. Velacor Therapeutics Pty Ltd